Zai Lab (NASDAQ:ZLAB) CFO Yajing Chen Sells 619 Shares

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.00, for a total transaction of $15,475.00. Following the transaction, the chief financial officer owned 35,072 shares of the company’s stock, valued at $876,800. This trade represents a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Yajing Chen also recently made the following trade(s):

• On Friday, June 26th, Yajing Chen sold 2,264 shares of Zai Lab stock. The stock was sold at an average price of $17.46, for a total transaction of $39,529.44.

Zai Lab Price Performance

Shares of Zai Lab stock opened at $26.03 on Friday. Zai Lab Limited Unsponsored ADR has a 1 year low of $15.96 and a 1 year high of $36.77. The firm has a market cap of $2.96 billion, a PE ratio of -15.22 and a beta of 0.78. The company has a 50 day simple moving average of $19.40 and a two-hundred day simple moving average of $19.44.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. The company had revenue of $106.31 million during the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%. As a group, research analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.17 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on ZLAB. Citigroup increased their target price on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Wall Street Zen lowered Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Finally, Zacks Research upgraded Zai Lab from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zai Lab has a consensus rating of “Moderate Buy” and an average price target of $40.20.

Hedge Funds Weigh In On Zai Lab

A hedge fund recently raised its position in Zai Lab stock. Royal Bank of Canada boosted its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,771 shares of the company’s stock after acquiring an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 41.65% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.